Feature | Radiation Therapy | May 10, 2019

Varian Acquires CyberHeart Cardiac Radio-ablation Technology

Technology enables electrophysiology ablations using radiotherapy to treat cardiac arrhythmias

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation, in green. The blue shows critical structures in the area around the heart that should be avoided by the radiation beam.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation, in green. The blue shows critical structures in the area around the heart that should be avoided by the radiation beam.

May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has developed technology to use radiation therapy in the heart (cardiac radio-ablation) and other forms of radiosurgery for cardiovascular disease. This technology signals the company's entry into cardiology with a first of its kind technology that could represent a pardigm shift in electrophysiology (EP) ablation procedures. 

The use of radiation therapy systems to pin-point target cardiac tissues to ablate would eliminate the need catheter-based ablation therapies. Which are currently the standard of care. If successful in clinical trials, this technology could make these long, involved catheter-based EP procedures obsolete, in favor of a noninvasive. Therapy where the patient does not need to be catheterized. This has been a hot topic in future innovation sessions at both the Heart Rhythm Society (HRS)American Association of Physicists in Medicine (AAPM) and the American Society for Radiation Oncology (ASTRO) the past few years.  

The Cyberheart system would have application to treat atrial fibrillation, where current technologies leave room for improvement because of long procedure times of several hours and success rates only in the 70 percent range, said Hugh Calkins, M.D., FACC, FAHA, FHRS, director of cardiac arrhythmia services and professor of medicine at Johns Hopkins Hospital. He said this novel technology might be able greatly simplify and speed up Afib treatments. "It would be really amazing if it really works, but with all these things, we just need more data," Calkins said.

"Based on the early positive clinical results in ventricular tachycardia we have seen from other investigators, we believe that this technology can offer hope to cardiac arrhythmia patients," said Dee Khuntia, chief medical officer at Varian. "Cardiac radioablation would truly be a paradigm shift, bringing together two specialties—radiation oncology and cardiac electrophysiology—to collaborate in the treatment of cardiac patients."

"Varian has a long track record of innovations in the field of radiation medicine and has successfully commercialized radiosurgery technology for treating both benign and malignant lesions," said Kolleen Kennedy, president of Varian proton solutions and chief growth officer. "We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space."

First in-human studies of radioablation in the treatment of cardiac arrhythmias have been published in the New England Journal of Medicine and Circulation.[1,2]

"While cardiac radioablation technologies are not yet approved by the FDA, we feel that the results of these recent early studies are promising enough to warrant investment in this area," Kennedy said.  "We're now working to evaluate the CyberHeart intellectual property portfolio and determine priorities for development and clinical trials going forward."

 

 

Related Content

New Technologies to Improve Atrial Fibrillation Ablation

New Targets for Radiation Therapy Include Cardiac AF Ablations and Renal Denervation

VIDEO: Using Radiosurgery for Atrial Fibrillation Cardiac Ablation

CyberHeart to Develop Noninvasive Cardiac Ablation Technique Using Accuray Robotic System

 

References:
1. Cuculich, Phillip S., et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. New England Journal of Medicine 377.24 (2017): 2325-2336.

2. Robinson, Clifford G., et al. Phase I/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia. Circulation 139.3 (2019): 313-321.

Related Content

Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Feature | Proton Therapy | May 27, 2020 | By Minesh Mehta, M.D.
Radiation therapy has advanced significantly in the last few decades as a result of a continued technological revolut
Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve.

Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve. Getty Images

Feature | Oncology Information Management Systems (OIMS) | May 27, 2020 | By Reshu Gupta
In the history of medicine, researchers have found cures for many diseases, but cancer has been elusive.
Off-site imaging companies are playing a key role in the fight against COVID-19
Feature | Coronavirus (COVID-19) | May 26, 2020 | By Sean Zahniser
After the worst of the COVID-19 pandemic has pas
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue

A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue. Image courtesy of Xiandoing Xue, UC Davis

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers at the University of California, Davis offers a...
Despite facing challenges such as limited access to personal protective equipment (PPE) following the COVID-19 outbreak, radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO).

Getty Images

News | Coronavirus (COVID-19) | May 21, 2020
May 21, 2020 — Despite facing challenges such as limited access to...
In response to the significant healthcare delivery changes brought on by COVID-19, Varian has launched new capabilities for its Noona software application, a powerful tool designed to engage cancer patients in their care for continuous reporting and symptom monitoring.
News | Radiation Oncology | May 21, 2020
May 21, 2020 — In response to the significant healthcare delivery changes brought on by...
The global radiation therapy market is expected to reach $10.11 billion in 2024, witnessing growth at a CAGR of 3.38%, over the period 2020-2024.
News | Proton Therapy | May 20, 2020
May 20, 2020 — ResearchAndMarkets.com has released its latest report, the ...